STING-ATF3/type I interferon crosstalk: A potential target to improve anti-tumour immunity in chemotherapy-treated urothelial carcinoma

Clin Transl Med. 2024 Sep;14(9):e70011. doi: 10.1002/ctm2.70011.
No abstract available

Publication types

  • Letter

MeSH terms

  • Activating Transcription Factor 3* / metabolism
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Humans
  • Interferon Type I* / immunology
  • Interferon Type I* / metabolism
  • Interferon Type I* / therapeutic use
  • Membrane Proteins
  • Urologic Neoplasms / drug therapy
  • Urologic Neoplasms / immunology

Substances

  • Interferon Type I
  • Activating Transcription Factor 3
  • Membrane Proteins
  • STING1 protein, human
  • ATF3 protein, human
  • Antineoplastic Agents